A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295,an Oral Inhibitor of the Kinesin Motor Protein KIF18A, in Patients with Locally Advanced or Metastatic Solid Tumors, including High-Grade Serous Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
Why this Research Matters
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
Who can Participate
Detailed eligibility criteria is available on ClinicalTrials.gov. These requirements will be discussed with your doctor and/or study representative. Go to ClinicalTrials.gov to learn more about this study. https://clinicaltrials.gov/study/NCT06799065?intr=ATX-295&viewType=Card&rank=1
Study ID
Protocol Number: 26-0522
More information available at ClinicalTrials.gov: NCT06799065
Meet the Team
Principal Investigator